ReviewClinical reviews in allergy & immunology2026
The Application of Single-cell RNA Sequencing Technology in the Research of Sino-Nasal Diseases.
Review in Clinical reviews in allergy & immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Single-cell RNA sequencing (scRNA-seq) has revolutionized rhinology by enabling the high-resolution dissection of nasal pathophysiology at the genetic level. This article provides a comprehensive overview of scRNA-seq technology and discusses the progressive developments in its application for diagnosing diseases in rhinology, chiefly infective nasal diseases and chronic inflammatory states. It has been instrumental in identifying infection-related genes, linking cellular dynamics to clinical variables such as age and smoking, and deconvoluting complex diseases like chronic rhinosinusitis (CRS) and allergic rhinitis(AR) by defining key pathogenic cells (e.g., ALOX15+ macrophages) and novel pathways like glycolysis. The integration of scRNA-seq with spatial transcriptomics and multi-omics approaches is also discussed in this article, promising deeper insights into nasal biology and future therapeutic strategies, while current technological limitations are acknowledged.
Indexed as
Identifiers
41849011What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.